Powered by

Akcea and Ionis to Present New Data for TEGSEDI and AKCEA-TTR-LRx at Two Upcoming Medical Meetings

Aug 29, 2019 - GlobeNewswire

Multiple presentations on the long-term efficacy and safety of TEGSEDIĀ® (inotersen) in patients with polyneuropathy caused by hATTR Amyloidosis

Topline data results to be presented from the Phase 1 study of AKCEA-TTR-LRx for the treatment of Transthyretin Amyloidosis (TTR)

BOSTON and CARLSBAD, Calif., Aug. 29, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announce...